Alligator Bioscience Showcases Promising OPTIMIZE-1 Trial Results at ASCO 2025

Alligator Bioscience AB ( (SE:ATORX) ) has provided an update.

Alligator Bioscience presented promising biomarker data from its OPTIMIZE-1 clinical trial at the ASCO 2025 Annual Meeting, highlighting the efficacy of mitazalimab in combination with mFOLFIRINOX for treating metastatic pancreatic cancer. The trial results, which include a significant survival rate and objective response rate, support further development of mitazalimab and underscore its potential impact on the treatment landscape for pancreatic cancer. The company’s participation at ASCO also underscores its commitment to scientific exchange and strategic business development.

More about Alligator Bioscience AB

Alligator Bioscience is a clinical-stage biotechnology company based in Lund, Sweden, specializing in the development of tumor-directed immuno-oncology antibody drugs targeting the CD40 receptor. This approach aims to enhance the priming of tumor-specific T cells and counteract the immunosuppressive tumor microenvironment, offering potential benefits for cancer patients across various types of cancer. The company’s lead drug candidate, mitazalimab, is advancing towards Phase 3 development and has shown promising survival data in metastatic pancreatic cancer patients.

Average Trading Volume: 243,767

Current Market Cap: SEK65.93M

For a thorough assessment of ATORX stock, go to TipRanks’ Stock Analysis page.